1028 Arena Longboard
BioCentury & Getty Images

Emerging Company Profile

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

Emerging Company Profile: Longboard has three programs that each share targets with existing Arena molecules

Longboard Pharmaceuticals raises its first cash from a syndicate led by Farallon Capital and spins out of Arena with three programs that each share a target with an existing molecule from the parent company.

Oct 28, 2020 | 11:25 PM GMT

With $56 million in fresh funding from a

Read the full 840 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE